S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Better Than Oil Stocks? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Better Than Oil Stocks? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Better Than Oil Stocks? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Better Than Oil Stocks? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Forecast, Price & News

$7.75
+0.03 (+0.39%)
(As of 09/29/2023 ET)
Compare
Today's Range
$7.58
$7.86
50-Day Range
$7.55
$10.23
52-Week Range
$4.77
$14.34
Volume
622,219 shs
Average Volume
255,132 shs
Market Capitalization
$340.23 million
P/E Ratio
3.41
Dividend Yield
N/A
Price Target
$17.00

Voyager Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
119.4% Upside
$17.00 Price Target
Short Interest
Bearish
5.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.69mentions of Voyager Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$145,080 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $1.11 to ($1.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

297th out of 972 stocks

Biological Products, Except Diagnostic Industry

44th out of 155 stocks


VYGR stock logo

About Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

VYGR Price History

VYGR Stock News Headlines

Med-Tech Stock Set To Rally!
With All The News That This Bio- Tech Stock Has had It Could Be Set To Rally!
Med-Tech Stock Set To Rally!
With All The News That This Bio- Tech Stock Has had It Could Be Set To Rally!
Voyager's Danny Estrin shares 'devastating' cancer diagnosis
See More Headlines
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Company Calendar

Last Earnings
8/03/2023
Today
9/30/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+119.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-46,410,000.00
Pretax Margin
49.58%

Debt

Sales & Book Value

Annual Sales
$40.91 million
Book Value
$1.53 per share

Miscellaneous

Free Float
41,838,000
Market Cap
$340.23 million
Optionable
Optionable
Beta
1.03
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Alfred W. Sandrock Jr. (Age 65)
    M.D., Ph.D., Pres, CEO & Director
    Comp: $825.41k
  • Mr. Peter P. Pfreundschuh CPA (Age 54)
    Chief Financial Officer
    Comp: $172.73k
  • Dr. Krystof Bankiewicz M.D.
    Ph.D., Founder
  • Dr. Guangping Gao Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Mark A. Kay M.D. (Age 64)
    Ph.D., Founder
  • Dr. Phillip D. Zamore Ph.D.
    Founder & Member of Scientific Advisory Board
  • Ms. Robin Swartz (Age 52)
    Chief Operating Officer
  • Mr. Todd Carter Ph.D. (Age 53)
    Chief Scientific Officer
  • Ms. Jacquelyn Fahey Sandell Esq.
    J.D., Chief Legal Officer
  • Ms. Michelle Quinn Smith
    Chief HR Officer













VYGR Stock - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VYGR shares.
View VYGR analyst ratings
or view top-rated stocks.

What is Voyager Therapeutics' stock price forecast for 2023?

3 Wall Street analysts have issued 1-year price objectives for Voyager Therapeutics' shares. Their VYGR share price forecasts range from $16.00 to $18.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 119.4% from the stock's current price.
View analysts price targets for VYGR
or view top-rated stocks among Wall Street analysts.

How have VYGR shares performed in 2023?

Voyager Therapeutics' stock was trading at $6.10 at the beginning of the year. Since then, VYGR stock has increased by 27.0% and is now trading at $7.75.
View the best growth stocks for 2023 here
.

When is Voyager Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our VYGR earnings forecast
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.08. The company had revenue of $4.85 million for the quarter, compared to analyst estimates of $2 million.

What ETF holds Voyager Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 4,243 shares of VYGR stock, representing 0.82% of its portfolio.

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $7.75.

How much money does Voyager Therapeutics make?

Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $340.23 million and generates $40.91 million in revenue each year. The company earns $-46,410,000.00 in net income (profit) each year or $2.27 on an earnings per share basis.

How many employees does Voyager Therapeutics have?

The company employs 125 workers across the globe.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com.

This page (NASDAQ:VYGR) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -